- Home
- BY vs PCRX Comparison
BY vs PCRX Comparison
Compare BY & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BY
- PCRX
- Stock Information
- Founded
- BY 1914
- PCRX 2006
- Country
- BY United States
- PCRX United States
- Employees
- BY N/A
- PCRX N/A
- Industry
- BY Major Banks
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- BY Finance
- PCRX Health Care
- Exchange
- BY Nasdaq
- PCRX Nasdaq
- Market Cap
- BY 1.3B
- PCRX 1.2B
- IPO Year
- BY 2017
- PCRX 2011
- Fundamental
- Price
- BY $28.95
- PCRX $27.15
- Analyst Decision
- BY Hold
- PCRX Buy
- Analyst Count
- BY 3
- PCRX 6
- Target Price
- BY $33.00
- PCRX $30.00
- AVG Volume (30 Days)
- BY 183.9K
- PCRX 634.1K
- Earning Date
- BY 10-23-2025
- PCRX 11-05-2025
- Dividend Yield
- BY 1.38%
- PCRX N/A
- EPS Growth
- BY N/A
- PCRX N/A
- EPS
- BY 2.68
- PCRX N/A
- Revenue
- BY $384,591,000.00
- PCRX $705,848,000.00
- Revenue This Year
- BY $17.79
- PCRX $7.36
- Revenue Next Year
- BY $3.36
- PCRX $10.07
- P/E Ratio
- BY $10.84
- PCRX N/A
- Revenue Growth
- BY 2.48
- PCRX 2.25
- 52 Week Low
- BY $22.63
- PCRX $12.61
- 52 Week High
- BY $32.89
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- BY 58.61
- PCRX 64.64
- Support Level
- BY $28.59
- PCRX $25.63
- Resistance Level
- BY $29.75
- PCRX $27.46
- Average True Range (ATR)
- BY 0.71
- PCRX 0.94
- MACD
- BY -0.04
- PCRX -0.03
- Stochastic Oscillator
- BY 80.34
- PCRX 80.40
About BY Byline Bancorp Inc.
Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.